Zobrazeno 1 - 10
of 342
pro vyhledávání: '"Alexis Ogdie"'
Autor:
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alice B. Gottlieb
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many patients with PsA are TNFi inadequate responders (TNF-IR; either inadequate efficacy
Externí odkaz:
https://doaj.org/article/8af8899c7fd64bf9a16ff7465d160dd3
Autor:
Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Ruizhi Sophia Zhao, Soumya D. Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 5, Pp 304-311 (2024)
Objective Evaluate patient‐reported outcomes after 6 months of on‐label guselkumab use in patients with rheumatologist‐diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/Spondyloarthritis Registry. Methods This analysis in
Externí odkaz:
https://doaj.org/article/197c05cdb19f4b9fb26fe2baaf5f58b3
Autor:
Philip J. Mease, Pamela Young, Lara Fallon, Rajiv Mundayat, Oluwaseyi Dina, Taylor Blachley, Nicole Middaugh, Alexis Ogdie
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 2, Pp 313-329 (2024)
Abstract Introduction Randomized controlled trials have demonstrated tofacitinib efficacy for psoriatic arthritis (PsA); however, real-world effectiveness data are limited. This real-world analysis assessed baseline demographics/disease characteristi
Externí odkaz:
https://doaj.org/article/7cf6d725968f442b82ef8a79b8f60232
Autor:
Joshua F. Baker, Marianna Olave, William Leach, Caleigh R. Doherty, Rachel L. Gillcrist, Daniel K. White, Alexis Ogdie, Bryant R. England, Katherine Wysham, Mercedes Quinones, Rui Xiao, Tuhina Neogi, Carla R. Scanzello
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 10, Pp 529-535 (2023)
Objective To quantify the effect of corticosteroids compared to lidocaine‐only injections over 12 weeks among patients with knee osteoarthritis (KOA). Methods Participants with KOA were randomized to receive a knee injection of methylprednisolone a
Externí odkaz:
https://doaj.org/article/1b48e8ad52744e149066a45eb0d65daa
Autor:
Laure Gossec, Ana-Maria Orbai, Maarten de Wit, Dafna D Gladman, Laura C Coates, Alexis Ogdie, Vanessa Taieb, Jeremy Lambert, Barbara Ink, Christopher G Pelligra, Valérie Ciaravino
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objectives To investigate psychometric performance of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) total and individual item scores in patients with psoriatic arthritis (PsA) and to estimate score change thresholds and scores correspo
Externí odkaz:
https://doaj.org/article/aa2336a6b90d4afeb287bfb5c55eaac9
Autor:
Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1479-1501 (2023)
Abstract Introduction The aim of this work is to evaluate treatment persistence and clinical outcomes after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/S
Externí odkaz:
https://doaj.org/article/670a15e0810945e28ecb889c8800099e
Autor:
Philip J. Mease, Jacqueline O'Brien, Nicole Middaugh, Gregory Kricorian, Scott Stryker, David H. Collier, Alexis Ogdie
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 8, Pp 388-398 (2023)
Objective Real‐world studies assessing treatment response by psoriatic arthritis (PsA) domains are limited. This study aimed to describe the patient characteristics, frequency and combinations of disease domains, disease activity, and patient‐rep
Externí odkaz:
https://doaj.org/article/e7cde6931ae94e99a1ad7f49603618fd
Autor:
Alexis Ogdie, Dafna D. Gladman, Laura C. Coates, Effie Pournara, Bhumik Parikh, Philip J. Mease
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 849-860 (2023)
Abstract Introduction This study evaluated the efficacy of the interleukin-17A inhibitor secukinumab in patients with oligoarticular psoriatic arthritis (PsA). Methods A total of 84 patients with oligoarticular PsA, defined as 1–4 tender joints and
Externí odkaz:
https://doaj.org/article/679764b5716048f09357290428f17f2e
Autor:
Joseph F. Merola, Alexis Ogdie, Alice B. Gottlieb, Linda Stein Gold, Andrea Flower, Shauna Jardon, Yuri Klyachkin, Mark Lebwohl
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 6, Pp 1329-1346 (2023)
Abstract Introduction The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey study was conducted globally in 2020 to understand how disease perceptions, including disease severity, treatment goals, and quality of life (
Externí odkaz:
https://doaj.org/article/95ba153e8f0e480eb2523dcc8867f3ba
Autor:
Alexis Ogdie, Yomei Shaw, Michele Almonte, Ervant J. Maksabedian Hernandez, Bradley Stolshek, Kaleb Michaud
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 4, Pp 167-172 (2023)
Objective To describe patients’ perspectives on the burden associated with methotrexate (MTX) or tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Methods Between May 2019 and March 2020, patient
Externí odkaz:
https://doaj.org/article/eb5baf57a6fe4138a9b3bf433fa5c73e